NCT00721474

Brief Summary

A Study to determine if a high-fat meal has an effect on the pharmacokinetics of bosutinib.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Sep 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 22, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 24, 2008

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2008

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2008

Completed
Last Updated

February 6, 2009

Status Verified

February 1, 2009

Enrollment Period

Same day

First QC Date

July 22, 2008

Last Update Submit

February 5, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pharmacokinetics (plasma concentrations)

    4 weeks

Study Arms (2)

1

EXPERIMENTAL

Bosutinib fasting

Drug: Bosutinib

2

EXPERIMENTAL

Bosutinib fed

Drug: Bosutinib

Interventions

Bosutinib fasting

1

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men, age 18-50;
  • Healthy women of nonchildbearing potential, age 18-50.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Tacoma, Washington, 98418, United States

Location

MeSH Terms

Interventions

bosutinib

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

July 22, 2008

First Posted

July 24, 2008

Study Start

September 1, 2008

Primary Completion

September 1, 2008

Study Completion

September 1, 2008

Last Updated

February 6, 2009

Record last verified: 2009-02

Locations